ATE270898T1 - Stabile igf/igfbp pharmazeutische formulierungen - Google Patents

Stabile igf/igfbp pharmazeutische formulierungen

Info

Publication number
ATE270898T1
ATE270898T1 AT99955220T AT99955220T ATE270898T1 AT E270898 T1 ATE270898 T1 AT E270898T1 AT 99955220 T AT99955220 T AT 99955220T AT 99955220 T AT99955220 T AT 99955220T AT E270898 T1 ATE270898 T1 AT E270898T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
stable igf
Prior art date
Application number
AT99955220T
Other languages
English (en)
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE270898T1 publication Critical patent/ATE270898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99955220T 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen ATE270898T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (1)

Publication Number Publication Date
ATE270898T1 true ATE270898T1 (de) 2004-07-15

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955220T ATE270898T1 (de) 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen

Country Status (14)

Country Link
US (2) US6436897B2 (de)
EP (1) EP1082133B1 (de)
JP (1) JP2002516871A (de)
KR (1) KR20010052500A (de)
CN (1) CN1201816C (de)
AT (1) ATE270898T1 (de)
AU (1) AU4326799A (de)
BR (1) BR9910863A (de)
CA (1) CA2330925C (de)
DE (1) DE69918690T2 (de)
ES (1) ES2221456T3 (de)
HK (1) HK1040637B (de)
IL (1) IL139969A0 (de)
WO (1) WO1999062536A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
RU2442822C2 (ru) * 2005-01-25 2012-02-20 Вайет Рисерч Айрлэнд Лимитед Вещества, защищающие клетки от рассечения при сборе микрофильтрацией
PL1861116T3 (pl) * 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
EP3673919A1 (de) 2005-06-14 2020-07-01 Amgen Inc. Selbstpuffernde proteinformulierungen
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
AU2007291501B2 (en) 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
WO2010096125A1 (en) * 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
NZ600454A (en) 2009-11-30 2014-10-31 Univ Queensland Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013116847A1 (en) * 2012-02-03 2013-08-08 Charm Sciences, Inc. Extraction of mycotoxins
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
WO2016209773A1 (en) * 2015-06-22 2016-12-29 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
WO2017117236A1 (en) * 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
EP3522867A1 (de) 2016-10-07 2019-08-14 Regeneron Pharmaceuticals, Inc. Raumtemperaturstabiles lyophilisiertes protein
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
CA3194764A1 (en) * 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
EP0726911B1 (de) 1993-09-20 2002-10-30 Celtrix Pharmaceuticals, Inc. Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
JPH09509140A (ja) 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
EP0732933B1 (de) * 1993-11-15 2002-10-09 Celtrix Pharmaceuticals, Inc. Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
US20030087806A1 (en) 2003-05-08
WO1999062536A2 (en) 1999-12-09
ES2221456T3 (es) 2004-12-16
WO1999062536A3 (en) 2000-03-30
EP1082133A2 (de) 2001-03-14
US20020004478A1 (en) 2002-01-10
EP1082133B1 (de) 2004-07-14
DE69918690T2 (de) 2005-08-18
CN1201816C (zh) 2005-05-18
JP2002516871A (ja) 2002-06-11
CA2330925A1 (en) 1999-12-09
CA2330925C (en) 2010-02-09
KR20010052500A (ko) 2001-06-25
IL139969A0 (en) 2002-02-10
BR9910863A (pt) 2002-06-11
HK1040637A1 (en) 2002-06-21
AU4326799A (en) 1999-12-20
HK1040637B (zh) 2006-01-06
US6436897B2 (en) 2002-08-20
CN1315868A (zh) 2001-10-03
DE69918690D1 (de) 2004-08-19

Similar Documents

Publication Publication Date Title
DE69918690D1 (de) Stabile igf/igfbp pharmazeutische formulierungen
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
IL140710A0 (en) Pulmonary delivery of active agents
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
PT1058558E (pt) Vacinas vivas recombinantes administradas com adjuvante
FI952119A (fi) Stabiili pakastekuivattu koostumus, joka sisältää proteiinia ja testipakkaus
DK2130554T3 (da) Albuminfrie faktor VIII-præparater
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
NO20021333D0 (no) Sammensetning som innbefatter kasein- og myseprotein
NO20020526L (no) Moksifloksasinformulering med koksalt
BR0012429A (pt) Fórmulações para il-11
BR9811094A (pt) Agente terapêutico para tumores linfáticos
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
DE69004004D1 (de) Kolloidales Fluorid und orale Zusammensetzung.
PT1220693E (pt) Formulacoes para libertacao de proteinas osteogenicas
ATE262923T1 (de) Pharmazeutische zusammensetzung aus fibrinolytischem mittel
SE9702680D0 (sv) New formulation
DK1014987T3 (da) Orale præparater med levosimendan
DE68903858D1 (de) Orale mittel fuer wiederkaeuer.
EE04954B1 (et) Peroraalselt v?i paikselt manustatav farmatseutiline preparaat ja selle ravimvorm
DK0759775T3 (da) Flydende IFN-beta-formuleringer
SE9402880D0 (sv) New peptide derivatives
SE9604795D0 (sv) New pharmaceutical formulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082133

Country of ref document: EP